MOR.SG - MORPHOSYS AG Inhaber-Aktien o.N
| Previous close | 97.00 |
| Open | 96.50 |
| Bid | 96.95 x 27700 |
| Ask | 97.60 x 21000 |
| Day's range | 95.80 - 97.50 |
| 52-week range | 76.45 - 114.60 |
| Volume | 1,515 |
| Avg. volume | 1,726 |
| Market cap | N/A |
| Beta (3Y monthly) | N/A |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- EQS Group
MorphoSys AG: Preliminary announcement of the publication of financial reports according to Articles 114, 115, 117 of the WpHG [the German Securities Act]
MorphoSys AG / Preliminary announcement on the disclosure of financialstatements17.12.2018 / 14:02Preliminary announcement of the publication of financial reports accordingto Articles 114, 115, 117 of the WpHG [the German Securities Act]transmitted by DGAP - a service of EQS Group AG.The issuer is solely responsible for the content of this announcement. ...
- EQS Group
MorphoSys AG: Preliminary announcement of the publication of quarterly reports and quarterly/interim statements
MorphoSys AG / Preliminary announcement on the disclosure of financialstatements17.12.2018 / 14:02Preliminary announcement of the publication of quarterly reports andquarterly/interim statements transmitted by DGAP - a service of EQS GroupAG.The issuer is solely responsible for the content of this announcement. ...
- EQS Group
MorphoSys AG: Corporate Calendar 2019 (news with additional features)
DGAP-News: MorphoSys AG / Key word(s): Miscellaneous17.12.2018 / 14:00 The issuer is solely responsible for the content of this announcement.
- EQS Group
MorphoSys's Licensee Janssen Announces Data from the Phase 3 Head-to-Head Study ECLIPSE Demonstrating Superiority of Tremfya(R) vs. Cosentyx(R) as Measured by PASI 90 at Week 48 in the Treatment of Plaque Psoriasis (news with additional features)
DGAP-News: MorphoSys AG / Key word(s): Study results12.12.2018 / 13:36 The issuer is solely responsible for the content of this announcement.
- EQS Group
Ad hoc: MorphoSys Announces that According to a Presentation Title at an Upcoming Conference, Guselkumab Demonstrates Superior Long-Term Responses to Secukinumab at Week 48 in the Treatment of Moderate to Severe Psoriasis
MorphoSys AG / Key word(s): MiscellaneousAd hoc: MorphoSys Announces that According to a Presentation Title at an Upcoming Conference, Guselkumab Demonstrates Superior Long-Term Responses to Secukinumab at Week 48 in the Treatment of Moderate to Severe Psoriasis07-Dec-2018 / 13:21 CET/CESTDisclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by DGAP - a service of EQS Group AG.The issuer is solely responsible for the content of this announcement.
- EQS Group
MorphoSys Presents Updated Data from L-MIND Study of MOR208 plus Lenalidomide in r/r DLBCL at ASH 2018 (news with additional features)
DGAP-News: MorphoSys AG / Key word(s): Study results/Conference02.12.2018 / 01:00 The issuer is solely responsible for the content of this announcement.
- EQS Group
MorphoSys Announces Approval of Tremfya(R) (Guselkumab) in Japan for the Treatment of Patients with Palmoplantar Pustulosis (news with additional features)
DGAP-News: MorphoSys AG / Key word(s): Regulatory Approval26.11.2018 / 07:30 The issuer is solely responsible for the content of this announcement.
- EQS Group
MorphoSys to Present at Upcoming Investor Conferences
DGAP-News: MorphoSys AG / Key word(s): Conference21.11.2018 / 14:00 The issuer is solely responsible for the content of this announcement.
- EQS Group
MorphoSys Announces Its Licensee Janssen Initiated a Phase 2 Study (NOVA) to Evaluate Guselkumab in Hidradenitis Suppurativa (news with additional features)
DGAP-News: MorphoSys AG / Key word(s): Study19.11.2018 / 22:01 The issuer is solely responsible for the content of this announcement.
- EQS Group
MorphoSys and I-Mab Sign Strategic Partnering Agreement for MorphoSys's Novel Immuno-Oncology Agent MOR210 (news with additional features)
NASDAQ: MOR) and I-Mab Biopharma ("I-Mab"), a biotech company focusing exclusively on innovative biologics in immuno-oncology and autoimmune diseases, jointly announced today that they have entered into an exclusive strategic collaboration and regional licensing agreement for MOR210. MOR210 is MorphoSys's proprietary, preclinical-stage antibody directed against C5aR, which has potential to be developed as an immuno-oncology agent.
- EQS Group
MorphoSys AG Announces Third Quarter 2018 Results (news with additional features)
DGAP-News: MorphoSys AG / Key word(s): Quarterly / Interim Statement05.11.2018 / 22:01 The issuer is solely responsible for the content of this announcement.
- EQS Group
MorphoSys to Present Data on Investigational Drugs MOR208 and MOR202 in Various Blood Cancer Indications at ASH 2018 Meeting (news with additional features)
DGAP-News: MorphoSys AG / Key word(s): Conference01.11.2018 / 14:22 The issuer is solely responsible for the content of this announcement.
- EQS Group
MorphoSys to Host Q3 2018 Conference Call on November 6, 2018 (news with additional features)
DGAP-News: MorphoSys AG / Key word(s): Miscellaneous29.10.2018 / 14:00 The issuer is solely responsible for the content of this announcement.
- EQS Group
MorphoSys's Licensing Partner GSK has Reported Data on GSK3196165 from Phase 2 Study in Rheumatoid Arthritis to be Presented at the ACR Conference (news with additional features)
DGAP-News: MorphoSys AG / Key word(s): Study results/Conference21.10.2018 / 11:08 The issuer is solely responsible for the content of this announcement.
- EQS Group
MorphoSys's Licensee Janssen has Reported That New Tremfya(R) (Guselkumab) 3-Year Data Shows Stably Maintained Rates of Skin Clearance in Patients with Moderate to Severe Plaque Psoriasis (news with additional features)
DGAP-News: MorphoSys AG / Key word(s): Study19.10.2018 / 15:28 The issuer is solely responsible for the content of this announcement.